I can extract side effects

"Very good, sure. Come on, work hard."

Wei Kang closed the document, quickly signed it, and handed it to Tang Que who was opposite.

However, he thought about it and added a few words.

"By the way, the company's artificial intelligence research and development has made great progress recently. You can try to use it for drug screening or construct gene expression vectors."

Tang Kuang nodded and left silently.

He quickly split up the tasks and assigned them.

Two or three people formed a small team and received their own work.

The entire biological laboratory is like a gear that is fully powered, and it is running with great power.

They have to repeat two known routes first, so as to reproduce the medicines of the friends.

Tang Que could sense that this was not an easy task, but a test.

If you get stuck at this step, you won't be able to continue and research Sanqing's own medicine.

The reason is obvious. The idea of ​​a friend can be used, but the drug molecule and the virus carrier cannot be the same, so as not to violate the patent protection of the other party.

Otherwise, even if the corresponding gene therapy drugs are developed, they will also be trapped by intellectual property rights and cannot be truly made in China.

To bypass patent barriers and find your own drugs, it is obvious that you need to have an in-depth understanding of virology vectors and genomics. This is part of basic scientific research and requires solid accumulation. It cannot be done immediately if you just want to overtake.

Behind this is often the accumulation of decades of research in interdisciplinary disciplines such as biology, virology and molecular evolution.

He has a serious face and is ready to fight a protracted battle.

However, a week later, Tang Que sat in the office, glared at the two people in front of him, and blurted out with disbelief.

"What? Done?"

After watching for ten seconds, he frowned: "Are you sure?"

Opposite him is Jiang Kai, who is gentle and handsome. He is an alumnus of Chen Yiqing and holds a Ph.D. in Biology from Harvard. He returned to China at the same time as Xiang Gaofei. team leader.

Jiang Kai said slowly: "Yes, Novartis' Z drug analysis work is almost done, and the AVV9 adenovirus vector has also been constructed. The data display on the computer is perfect, and the cell experiment is 100% consistent."

Tang Que was a little confused: "Is it so fast?"

"The company's new AI software is used to construct the virus vector and study the interaction with its receptor, so the progress is extremely fast. When the sample is produced, we will conduct animal experiments as soon as possible for further effect verification."

There was another person standing next to him, a round man of medium build, who hurriedly nodded in agreement: "Indeed, the small molecule drugs on our side are also progressing very smoothly. After analyzing the drug targets, we quickly copied related drugs. Increased mRNA shearing is also ongoing in animal experiments."

Tang Que stroked the stubble on his chin, lost in thought.

After a while, he waved his hand and let the two people across him leave.

And he focused on looking at the relevant data and information.

After a long time, he let out a long breath: "Sure enough, it has been completed. This speed is far beyond expectations. I thought it would take at least two or three months to make any progress."

"It seems that this newly launched AI software is quite easy to use." He opened the software named AICell on the desktop and logged in.

The software is very powerful. Not only does it have a complete human gene database, but it can also design the genome like designing parts, insert various base pairs, and also have function prompts for various genes.

It is also possible to use amino acid components to design proteins, and then simulate the function realization in the human body, and even split them into individual chemical molecules.

It can also simulate the three-dimensional models of various cells, organs, and nervous system of the human body, and even simulate the interaction between them, perfectly reproducing the operation and structure of the entire human body.

In short, there are all the functions that he can think of, and those he can't think of.

Tang Que couldn't help but gasp in amazement.

"Awesome!"

"It seems that since the progress is greatly advanced, we can continue to the next step."

"The copied drug does not need to be clinically used, as long as the animal experiments can show the effect."

"The most important thing is to develop our own drugs, so the first thing is the choice of viral vectors."

The construction of gene expression vectors is the core part of genetic engineering. In terms of the selection of viral vectors, there are currently three common options: adenoviral vectors, lentiviral vectors, and retroviral vectors, each with its own advantages and disadvantages.

Lentiviral vectors can be integrated into the host genome, and can effectively infect neuronal cells, liver cells, cardiomyocytes, tumor cells, endothelial cells, stem cells and other types of cells, so as to achieve good gene therapy effect.

If patients use gene therapy drugs with lentiviral vectors, they can completely modify the disease-causing gene mutation, thereby completely curing the disease and becoming a normal person.

However, since the virus base integrates the host gene, it also raises concerns about its carcinogenicity and genome safety.

The advantages and disadvantages of adeno-associated virus AAV are relatively clear. For example, its genome structure is relatively simple, almost non-pathogenic, the threshold for modification and the concerns for treatment are easy to overcome, and it is generally believed that it will not be integrated into the genome.

These advantages make it the first approved gene therapy drug, but its overall load is limited, resulting in fewer functional elements introduced, and in the long run, there is also a slight risk of carcinogenicity.

Retrovirus is also integrated in the host genome, but it can only infect dividing cells, and its capacity is limited, so the scope of use is relatively narrow.

Therefore, the final choice will be between lentivirus and adenovirus.

"Lentivirus or Adenovirus? Lentivirus or Adenovirus?"

"One is safe to express, but it cannot completely become a normal person, and the other is effective for a long time, and can also inherit normal genes."

"It's really hard to make a choice!"

These two thoughts kept reverberating in Tang Que's mind. He needed to make a decision to choose a predetermined virus carrier before he could continue the research and development below.

"Is it for once and for all or just for now?"

"Should I go crazy and choose the most permanent solution?"

"After all, the original intention of gene therapy is to bring patients back to normal. For genetic diseases, the focus is on genetics. If you choose a short-term route, it will not completely change the patient's life. If you give birth, the child born will naturally have a great chance of repeating the same mistakes. .”

"It's decided. Anyway, the research and development speed is so fast, and there is a lot of extra time. Let's study the lentiviral vector first."

"When we design a vector, we need to design the genome well, add insulator sequences and regulatory sequences to optimize it, and at the same time improve the packaged plasmid to increase safety."

"First conduct in-depth simulation in AICell, fully understand all the data, and then make samples, and use them for experiments on animals. Safety must be the first priority."

"However, if there is a risk of cancer, at least cancer can be treated, and the price is not too expensive. Compared with the 14 million SMA treatment cost, it is not so hopeless."

"If this route is not smooth, then follow Novartis to continue the research on adenovirus vectors, as long as different serotypes are used. I remember that Novartis is AVV9, and we can use AVV8 or others."

After he made a decision, he buried himself in his desk and started working.

List the tasks one by one and assign them to the team.

Then adjust for different progressions.

Fortunately, most of the preliminary work can now be done in software, which will greatly reduce the workload.

At that time, we only need to do cell experiments to verify it.